Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma

OBJECTIVE: Currently, treatment of relapsed or refractory multiple myeloma is challenging. Although bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE), a potent combination of a proteasome inhibitor, immunomodulatory drug, and conventional chemotherapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Togano, Tomiteru, Andoh, Shohei, Komuro, Masato, Mitsui, Yurika, Itoi, Satoru, Hirai, Risen, Nakamura, Miki, Tanimura, Akira, Sekine, Rieko, Takeshita, Masataka, Miwa, Akiyoshi, Hagiwara, Shotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751732/
https://www.ncbi.nlm.nih.gov/pubmed/35466165
http://dx.doi.org/10.2169/internalmedicine.9097-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751732/
https://www.ncbi.nlm.nih.gov/pubmed/35466165
http://dx.doi.org/10.2169/internalmedicine.9097-21

Ejemplares similares